NeuroOne Medical Has Responded To The FDA's Questions Regarding Its Previous Submission Of A 510(k) For Its OneRF Ablation System. The Company Expects To Receive Additional Communication In Thirty Days Or Less
Portfolio Pulse from Benzinga Newsdesk
NeuroOne Medical has responded to the FDA's queries about its previous submission of a 510(k) for its OneRF Ablation System. The company anticipates further communication within the next 30 days.
November 07, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
NeuroOne Medical has addressed the FDA's questions about its OneRF Ablation System. The company is expecting further communication within a month.
NeuroOne Medical's response to the FDA's questions is a crucial step in the approval process for its OneRF Ablation System. The company's anticipation of further communication within 30 days suggests that the process is moving forward, although the outcome is still uncertain. This could potentially impact the company's stock in the short term, depending on the nature of the FDA's response.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100